ES2198496T5 - Un procedimiento para analisis in vitro de sustancias toxicas y alergenicas. - Google Patents
Un procedimiento para analisis in vitro de sustancias toxicas y alergenicas. Download PDFInfo
- Publication number
- ES2198496T5 ES2198496T5 ES96925215T ES96925215T ES2198496T5 ES 2198496 T5 ES2198496 T5 ES 2198496T5 ES 96925215 T ES96925215 T ES 96925215T ES 96925215 T ES96925215 T ES 96925215T ES 2198496 T5 ES2198496 T5 ES 2198496T5
- Authority
- ES
- Spain
- Prior art keywords
- class
- cells
- cytokines
- substance
- neopterin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000126 substance Substances 0.000 title claims abstract description 72
- 238000000034 method Methods 0.000 title claims abstract description 29
- 231100000331 toxic Toxicity 0.000 title claims abstract description 17
- 230000002588 toxic effect Effects 0.000 title claims abstract description 17
- 238000000338 in vitro Methods 0.000 title claims abstract description 14
- 238000004458 analytical method Methods 0.000 title abstract description 8
- 239000013566 allergen Substances 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims abstract description 31
- BMQYVXCPAOLZOK-UHFFFAOYSA-N neopterin Chemical compound OCC(O)C(O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-UHFFFAOYSA-N 0.000 claims abstract description 23
- 108090001007 Interleukin-8 Proteins 0.000 claims abstract description 18
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 14
- 208000026935 allergic disease Diseases 0.000 claims abstract description 13
- 210000000601 blood cell Anatomy 0.000 claims abstract description 8
- 230000035755 proliferation Effects 0.000 claims abstract description 7
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims abstract description 6
- 208000006673 asthma Diseases 0.000 claims abstract description 6
- 238000011156 evaluation Methods 0.000 claims abstract description 6
- 230000009610 hypersensitivity Effects 0.000 claims abstract description 6
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims abstract description 5
- 230000002009 allergenic effect Effects 0.000 claims abstract description 5
- 230000005951 type IV hypersensitivity Effects 0.000 claims abstract description 5
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims abstract description 5
- 230000007969 cellular immunity Effects 0.000 claims abstract description 4
- 230000003111 delayed effect Effects 0.000 claims abstract description 4
- 239000012895 dilution Substances 0.000 claims abstract description 3
- 206010039083 rhinitis Diseases 0.000 claims abstract description 3
- 230000000451 tissue damage Effects 0.000 claims abstract description 3
- 231100000827 tissue damage Toxicity 0.000 claims abstract description 3
- 102000004127 Cytokines Human genes 0.000 claims description 62
- 108090000695 Cytokines Proteins 0.000 claims description 62
- 210000004369 blood Anatomy 0.000 claims description 22
- 239000008280 blood Substances 0.000 claims description 22
- BMQYVXCPAOLZOK-XINAWCOVSA-N neopterin Chemical compound OC[C@@H](O)[C@@H](O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-XINAWCOVSA-N 0.000 claims description 20
- 102000004890 Interleukin-8 Human genes 0.000 claims description 17
- 239000003153 chemical reaction reagent Substances 0.000 claims description 12
- 210000001519 tissue Anatomy 0.000 claims description 11
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 10
- 108090001005 Interleukin-6 Proteins 0.000 claims description 10
- 108010002352 Interleukin-1 Proteins 0.000 claims description 9
- 102000003814 Interleukin-10 Human genes 0.000 claims description 9
- 108090000174 Interleukin-10 Proteins 0.000 claims description 9
- 108010002350 Interleukin-2 Proteins 0.000 claims description 9
- 102000000588 Interleukin-2 Human genes 0.000 claims description 9
- 230000002757 inflammatory effect Effects 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 8
- 230000028993 immune response Effects 0.000 claims description 8
- 108090000978 Interleukin-4 Proteins 0.000 claims description 7
- 230000007815 allergy Effects 0.000 claims description 7
- 230000006378 damage Effects 0.000 claims description 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 210000000265 leukocyte Anatomy 0.000 claims description 6
- 206010012442 Dermatitis contact Diseases 0.000 claims description 5
- 108010065805 Interleukin-12 Proteins 0.000 claims description 5
- 208000024780 Urticaria Diseases 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 239000002243 precursor Substances 0.000 claims description 5
- 238000013207 serial dilution Methods 0.000 claims description 5
- 108010002616 Interleukin-5 Proteins 0.000 claims description 4
- 208000010247 contact dermatitis Diseases 0.000 claims description 4
- -1 gamma-IFN Proteins 0.000 claims description 4
- 210000004969 inflammatory cell Anatomy 0.000 claims description 4
- 238000010186 staining Methods 0.000 claims description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 3
- 239000003104 tissue culture media Substances 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 210000002808 connective tissue Anatomy 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims description 2
- 230000003511 endothelial effect Effects 0.000 claims description 2
- 210000002919 epithelial cell Anatomy 0.000 claims description 2
- 210000002950 fibroblast Anatomy 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 230000036039 immunity Effects 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 18
- 239000002085 irritant Substances 0.000 abstract description 2
- 231100000021 irritant Toxicity 0.000 abstract description 2
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 239000003440 toxic substance Substances 0.000 abstract description 2
- 239000004744 fabric Substances 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 26
- 241001465754 Metazoa Species 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 210000000987 immune system Anatomy 0.000 description 9
- 229940104230 thymidine Drugs 0.000 description 9
- 238000003556 assay Methods 0.000 description 7
- 230000008105 immune reaction Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 206010067484 Adverse reaction Diseases 0.000 description 5
- 230000006838 adverse reaction Effects 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 239000003226 mitogen Substances 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 108010047620 Phytohemagglutinins Proteins 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000001885 phytohemagglutinin Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 241000238876 Acari Species 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 239000003317 industrial substance Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960001005 tuberculin Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 102100036841 C-C motif chemokine 1 Human genes 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 108700012434 CCL3 Proteins 0.000 description 1
- 102000000013 Chemokine CCL3 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101100172469 Escherichia coli (strain K12) envZ gene Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101000713104 Homo sapiens C-C motif chemokine 1 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 101150004219 MCR1 gene Proteins 0.000 description 1
- 102000034655 MIF Human genes 0.000 description 1
- 108060004872 MIF Proteins 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
- 101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 description 1
- 101000713102 Mus musculus C-C motif chemokine 1 Proteins 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 108090000742 Neurotrophin 3 Proteins 0.000 description 1
- 108090000099 Neurotrophin-4 Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108090000630 Oncostatin M Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- 101150077103 TPO gene Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000002925 chemical effect Effects 0.000 description 1
- 238000006757 chemical reactions by type Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 229940062713 mite extract Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- LUYQYZLEHLTPBH-UHFFFAOYSA-N perfluorobutanesulfonyl fluoride Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)S(F)(=O)=O LUYQYZLEHLTPBH-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9502409A SE506533C2 (sv) | 1995-07-03 | 1995-07-03 | En process för in vitro analys av substansers toxiska och allergena egenskaper samt användning av neopterin för att skilja mellan allergiska immunreaktioner |
| SE9502409 | 1995-11-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2198496T3 ES2198496T3 (es) | 2004-02-01 |
| ES2198496T5 true ES2198496T5 (es) | 2009-10-23 |
Family
ID=20398831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES96925215T Expired - Lifetime ES2198496T5 (es) | 1995-07-03 | 1996-07-03 | Un procedimiento para analisis in vitro de sustancias toxicas y alergenicas. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6046010A (enExample) |
| EP (1) | EP0866968B2 (enExample) |
| JP (1) | JP2000500330A (enExample) |
| AT (1) | ATE239918T1 (enExample) |
| AU (1) | AU724932B2 (enExample) |
| CA (1) | CA2236474A1 (enExample) |
| DE (1) | DE69628033T3 (enExample) |
| DK (1) | DK0866968T4 (enExample) |
| ES (1) | ES2198496T5 (enExample) |
| SE (1) | SE506533C2 (enExample) |
| WO (1) | WO1997016732A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2384141A1 (en) * | 1999-10-15 | 2001-04-26 | Novozymes A/S | A method for the assessment of allergenicity |
| US7415358B2 (en) | 2001-05-22 | 2008-08-19 | Ocimum Biosolutions, Inc. | Molecular toxicology modeling |
| US20030022250A1 (en) * | 2001-05-29 | 2003-01-30 | Dreskin Stephen C. | Functional IgE test methods and compositions |
| US7447594B2 (en) | 2001-07-10 | 2008-11-04 | Ocimum Biosolutions, Inc. | Molecular cardiotoxicology modeling |
| US7469185B2 (en) | 2002-02-04 | 2008-12-23 | Ocimum Biosolutions, Inc. | Primary rat hepatocyte toxicity modeling |
| US20040077104A1 (en) * | 2002-07-09 | 2004-04-22 | Valentino Montegrande | Antigen detection device |
| PL1708690T3 (pl) | 2003-11-17 | 2017-01-31 | Biomarin Pharmaceutical Inc. | Leczenie fenyloketonurii za pomocą BH4 |
| CN101132776A (zh) * | 2004-11-17 | 2008-02-27 | 生物马林药物股份有限公司 | 稳定的四氢生物喋呤片剂制剂 |
| EP2108959A1 (en) | 2005-09-16 | 2009-10-14 | Biovator Technologies AB | In vitro assay for identification of allergenic proteins |
| EP1905843A1 (en) * | 2006-09-29 | 2008-04-02 | Vlaamse Instelling voor Technologisch Onderzoek | Method for determining the allergic potential of a compound |
| JP5442185B2 (ja) * | 2007-04-24 | 2014-03-12 | 日本メナード化粧品株式会社 | 感作性物質評価方法 |
| US20100311068A1 (en) | 2007-12-18 | 2010-12-09 | Biovator Technologies Ab | Assay |
| US9216178B2 (en) | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
| CN109283210B (zh) * | 2017-07-20 | 2021-02-09 | 郭俊成 | 一种应用植物胶琼脂固化而快速简便检测毒性物质的方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4215275A1 (de) * | 1992-05-09 | 1993-11-11 | Merck Patent Gmbh | Mittel und Verfahren zur Behandlung von Körperflüssigkeiten bei der Bestimmung von Neopterin |
-
1995
- 1995-07-03 SE SE9502409A patent/SE506533C2/sv not_active IP Right Cessation
-
1996
- 1996-07-03 EP EP96925215A patent/EP0866968B2/en not_active Expired - Lifetime
- 1996-07-03 WO PCT/SE1996/000902 patent/WO1997016732A1/en not_active Ceased
- 1996-07-03 AU AU65379/96A patent/AU724932B2/en not_active Ceased
- 1996-07-03 US US09/066,292 patent/US6046010A/en not_active Ceased
- 1996-07-03 CA CA002236474A patent/CA2236474A1/en not_active Abandoned
- 1996-07-03 AT AT96925215T patent/ATE239918T1/de active
- 1996-07-03 DK DK96925215T patent/DK0866968T4/da active
- 1996-07-03 ES ES96925215T patent/ES2198496T5/es not_active Expired - Lifetime
- 1996-07-03 JP JP9517257A patent/JP2000500330A/ja active Pending
- 1996-07-03 DE DE69628033T patent/DE69628033T3/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2236474A1 (en) | 1997-05-09 |
| DK0866968T4 (da) | 2009-06-22 |
| DE69628033T8 (de) | 2005-03-10 |
| US6046010A (en) | 2000-04-04 |
| DE69628033T3 (de) | 2009-11-19 |
| SE9502409L (sv) | 1997-05-02 |
| ES2198496T3 (es) | 2004-02-01 |
| DE69628033T2 (de) | 2004-04-22 |
| AU6537996A (en) | 1997-05-22 |
| EP0866968A1 (en) | 1998-09-30 |
| DE69628033D1 (de) | 2003-06-12 |
| SE506533C2 (sv) | 1998-01-12 |
| EP0866968B2 (en) | 2009-05-06 |
| JP2000500330A (ja) | 2000-01-18 |
| SE9502409D0 (sv) | 1995-07-03 |
| WO1997016732A1 (en) | 1997-05-09 |
| AU724932B2 (en) | 2000-10-05 |
| DK0866968T3 (da) | 2003-09-01 |
| ATE239918T1 (de) | 2003-05-15 |
| EP0866968B1 (en) | 2003-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2198496T5 (es) | Un procedimiento para analisis in vitro de sustancias toxicas y alergenicas. | |
| JP6620130B2 (ja) | ハイスループット多重検出用システム、装置及び方法 | |
| US8871508B2 (en) | Cell-mediated immune response assay and kits therefor | |
| KR101352222B1 (ko) | 의료용 제품에서 비-내독소 발열성 오염물을 보다 잘검출할 수 있는 개선된 단핵구 활성화 시험 | |
| CA2745437C (en) | Method for diagnosing allergic reactions | |
| Hou et al. | Establishment of the reference intervals of lymphocyte function in healthy adults based on IFN-γ secretion assay upon phorbol-12-myristate-13-acetate/ionomycin stimulation | |
| JP3723882B2 (ja) | 抗原特異的リンパ球検出用マイクロウェルアレイチップ、抗原特異的リンパ球の検出法及び製造方法 | |
| DE60009533T2 (de) | Multiple analyse von zytokinen | |
| KR20090074026A (ko) | Ｉｐ-10에 기초한 면역학적 모니터링 | |
| WO2013184660A1 (en) | Methods for diagnosing osteoarthritis | |
| Stelmaszczyk-Emmel et al. | Th1, Th2, Th17, and regulatory cytokines in children with different clinical forms of allergy | |
| Ojeda et al. | TNFα production in whole blood cultures from healthy individuals | |
| Wood et al. | The development of an in vitro cellular assay for Johne’s disease in cattle | |
| JP6628178B2 (ja) | ＩｇＥ非依存性アレルギー疾患検査方法 | |
| USRE38423E1 (en) | Process for in vitro analysis of toxic and allergenic substances | |
| Dietsche | Microfluidic systems for quantitative analysis of secreted proteins at the single-cell level | |
| Joyce et al. | A system for assessment of monokine gene expression using human whole blood | |
| RU2423700C2 (ru) | Способ прижизненной диагностики трихинеллеза свиней | |
| Hamilton | The clinical immunology laboratory of the future | |
| RU2105975C1 (ru) | Способ определения фагоцитарной активности периферической крови | |
| Arslan et al. | Comparison of sanger sequencing and next generation sequencing methods for investigation of JAK2 Exon 12 mutations in follow-up of patients with chronic myeloproliferative disease and JAK2 V617F non-mutation | |
| RU2038820C1 (ru) | Способ определения неспецифической резистентности организма свиней | |
| WO2021231504A1 (en) | Systems and methods for isolating and testing blood for biomarkers and genetic material | |
| Evans | The uses of serological epidemiology-abstract | |
| Faydi et al. | Laboratory Diagnosis of Brucellosis Using the Slide and Standard Tube Agglutination Methods |